bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Update

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 427,500 shares, a growth of 275.0% from the December 31st total of 114,000 shares. Based on an average daily trading volume, of 184,800 shares, the days-to-cover ratio is presently 2.3 days. Approximately 4.5% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC increased its stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,304 shares of the company’s stock after buying an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned about 0.30% of bioAffinity Technologies worth $42,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 1.64% of the company’s stock.

bioAffinity Technologies Stock Down 0.7 %

Shares of bioAffinity Technologies stock traded down $0.01 on Thursday, reaching $0.77. 50,438 shares of the company were exchanged, compared to its average volume of 310,660. The company has a market cap of $12.08 million, a P/E ratio of -0.94 and a beta of 2.98. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.02 and a quick ratio of 1.01. The stock’s 50 day moving average price is $0.94 and its 200-day moving average price is $1.49. bioAffinity Technologies has a 1-year low of $0.57 and a 1-year high of $3.62.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.